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Abstract
Background: Embryonic stem cell-specific gene (ESG) 1, which encodes a KH-domain containing
protein, is specifically expressed in early embryos, germ cells, and embryonic stem (ES) cells.
Previous studies identified genomic clones containing the mouse ESG1 gene and five pseudogenes.
However, their chromosomal localizations or physiological functions have not been determined.
Results: A Blast search of mouse genomic databases failed to locate the ESG1 gene. We identified
several bacterial artificial clones containing the mouse ESG1 gene and an additional ESG1-like
sequence with a similar gene structure from chromosome 9. The ESG1-like sequence contained a
multiple critical mutations, indicating that it was a duplicated pseudogene. The 5' flanking region of
the ESG1 gene, but not that of the pseudogene, exhibited strong enhancer and promoter activity
in undifferentiated ES cells by luciferase reporter assay. To study the physiological functions of the
ESG1  gene, we replaced this sequence in ES cells with a β-geo cassette by homologous
recombination. Despite specific expression in early embryos and germ cells, ESG1-/- mice developed
normally and were fertile. We also generated ESG1-/- ES cells both by a second independent
homologous recombination and directly from blastocysts derived from heterozygous intercrosses.
Northern blot and western blot analyses confirmed the absence of ESG1 in these cells. These ES
cells demonstrated normal morphology, proliferation, and differentiation.
Conclusion:  The mouse ESG1  gene, together with a duplicated pseudogene, is located on
chromosome 9. Despite its specific expression in pluripotent cells and germ cells, ESG1 is
dispensable for self-renewal of ES cells and establishment of germcells.
Background
Embryonic stem (ES) cells were first derived from the blas-
tocysts of mice in 1981 [1,2] and humans in 1998 [3]. ES
cells have two important properties: theability to main-
tain pluripotency, which is the ability to differentiate into
a wide variety of cells, and rapid proliferation. These char-
acteristics make mouse ES cells an essential component of
gene targeting technology. These qualitiesalso make
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human ES cells attractive sources for cell transplantation
therapy to treat various diseases, including spinal cord
injuries and juvenile diabetes. The molecular mechanisms
underlying the pluripotency and rapid proliferation of ES
cells are currently a major focus of the field of stem cell
biology [4-6].
To identify molecules essential in ES cells for these prop-
erties, several groups have utilized transcriptome analyses
to identify genes specifically expressed in ES cells and
early embryos. These analyses, including DNA microarray
analyses [7] and expressed sequence tag analyses [8-12],
identified several common transcripts, including ESG1
that was also designated dppa5 or ECAT2.
ESG1 was originally identified as a transcript Ph34 that
was down-regulated by retinoic acid in embryonic carci-
noma cells [13]. The expression of this gene was confined
in mice to early embryos and germ cells [14]. It is also
expressed in pluripotent cells, including ES cells, embry-
onic germ cells, and multipotent germline stem cells [15].
ESG1 encodes a polypeptide of 118 amino acids that con-
tains a single KH domain, which is an RNA-binding
domain [16]. It remains unclear, however, if ESG1 func-
tions as an RNA-binding protein or the roles it plays in ES
cells and mice.
Previous genomic library screening by identified genomic
clones containing the mouse ESG1 gene and seven pseu-
dogenes [17]. Two of these pseudogenes exhibit a similar
exon-intron structure as the ESG1 gene, indicating their
generation by gene duplication. The five remaining pseu-
dogenes did not contain any introns, indicating that these
were generated by retrotransposition of ESG1 transcripts.
ESG1 pseudogenes identified by a Blast search of mouse genomic databases Figure 1
ESG1pseudogenes identified by a Blast search of mouse genomic databases. Substitution mutations are indicated by 
black lines. Intron-like gap sequences are indicated with triangles. Chromosomal localizations are shown on the right.
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The chromosomal localizations of the mouse ESG1 gene
and pseudogenes, however, have not been reported.
In this study, we determined the structure of the mouse
gene encoding this protein and related pseudogenes. We
also performed gene targeting to determine the physiolog-
ical function of ESG1.
Results and discussion
Chromosomal localization and structures of mouse ESG1 
gene and psedogenes
To determine the chromosomal localizations of the
mouse ESG1 gene and pseudogenes, we performed a Blast
analysis of the mouse genomic database with the ESG1
cDNA sequence as a query. We identified several putative
pseudogenes without introns on chromosomes 1, 5, 11,
12, 14, 16, 17, and X (Figure 1). In addition, two intron-
less pseudogenes were identified in DNA fragments for
which the chromosomal localization remained
unmapped. While these pseudodgenes have significant
homology to ESG1 cDNA, they could not produce func-
tional proteins, because of critical mutations. This result
suggests that there are a larger number of intron-less pseu-
dogenes than previously anticipated. Existence of multi-
ple retropseudogenes is a hallmark of pluripotent cell-
specific genes [18].
On chromosome 9, we identified a DNA fragment similar
to the ESG1  gene that included two putative introns.
These putative first and second exons, however, contained
(4) multiple mutations of the ESG1 cDNA sequence. The
putative third exon was identical to that of the previously
reported ESG1 gene. Also on chromosome 9, we identi-
fied another DNA fragment that was similar, but not iden-
tical, to the third exon of the ESG1 gene. These findings
suggest that these ESG1-like sequences on chromosome 9
have not been correctly assembled.
To obtain DNA fragments containing the ESG1 gene, we
screened the bacterial artificial chromosome (BAC) DNA
pool by PCR using primer pairs that would only amplify
the real gene, not the pseudogenes. We obtained two inde-
pendent, but overlapping BAC clones. Southern blot anal-
yses and sequencing demonstrated that these clones
contained a sequence exhibiting complete identity with
ESG1 cDNA that was interrupted by two putative introns
(Figure 2A). The two intron sequences begin with GT and
terminate with AG, fulfilling the GT-AG rule of exon-
intron junctions [19]. The 5' flanking region of this DNA
fragment exhibited strong promoter/enhancer activity by
luciferase reporter assays in undifferentiated ES cells, but
not in somatic cells (Figure 3). The same fragment showed
much weaker activity after induction of differentiation by
retinoic acid. We concluded that this sequence is the ESG1
gene.
We also found that the two BAC clones contained another
ESG1-like sequence (Figure 2A). The two sequences, sepa-
rated by a 68 kbp intergenic sequence, were oriented in
opposite directions. The ESG1-like sequence exhibited
greater than 95% identity to the exons and introns of the
ESG1  gene. This sequence, however, contained critical
nucleotide substitutions in all of the exons and one nucle-
otide insertion in exon 2 (Figure 2B). Although 675 base
pairs of the 3' flanking regions were conserved between
the ESG1 gene and the pseudogene, only five base pairs of
the 5' flanking region were identical. This 5' flanking
region (~6 kbp) did not possess any promoter/enhancer
activity in luciferase reporter assays (Figure 3). It is thus
unlikely that this sequence is transcribed or translated
into a functional protein. This sequence likely represents
a duplication pseudogene. Bierbaum previously reported
the existence of two pseudogenes with similar exon-intron
organization as the ESG1 gene [17]. We could not deter-
mine which of these two pseudogenes corresponds to the
one we identified or the location of the remaining pseu-
dogene.
Targeted disruption of the mouse ESG1 gene
To study the function of ESG1, we deleted the gene by
homologous recombination in mouse ES cells. We
replaced the three exons with either a fusion of the neo-
mycin-resistance and β-galactosidase genes (β-geo) or the
hygromycin resistant gene (HygR) using two targeting vec-
tors (Figure 4A) introduced into RF8 ES cells by electropo-
ration. We obtained eight ES cell clones with correct
homologous recombination of the β-geo targeting vector,
which was confirmed by Southern blot analysis (Figure
4B). We obtained only one clone with correct homolo-
gous recombination of the HygR targeting vector.
To obtain homozygous mutant ES cells, we introduced
the β-geo vector into HygR heterozygous ES cells. Of 105
G418-resistant colonies tested, 49 were homozygous for
ESG1 deletion. Northern blot and western blot analyses
confirmed the absence of ESG1 in these cells (Figure 4C).
In 29 clones, the β-geo vector had replaced the HygR vec-
tor, such that the cells remained heterozygous. In the
remaining 27 clones, the β-geo vector was integrated at
non-homologous sites.
ESG1-/-  ES cells exhibited normal morphology (Figure
5A). These cells also proliferated at a speed comparable to
that of the control (heterozygous and wild-type) cells
(Figure 5B). ESG1-/- cells differentiated normally after the
removal of leukemia inhibitory factor (Figure 5B) or retin-
oic acid treatment (not shown). When transplanted into
hind flanks of nude mice, these cells produced teratomas,
tumors containing components of all three germ layers
(Figure 5C). These results indicate that ESG1 is dispensa-BMC Developmental Biology 2006, 6:11 http://www.biomedcentral.com/1471-213X/6/11
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ble for the self-renewal properties and pluripotency of ES
cells.
We examined the gene expression profiles of ESG1-/- ES
cells using oligonucleotide-based DNA microarrays repre-
senting ~20,000 genes. In comparison to control ES cells,
ESG1 was identified as the gene reduced to the greatest
extent in ESG1-/- ES cells (Figure 6A). The expression of ES
cell marker genes, such as Nanog and Oct3/4, was normal
in ESG1-/- ES cells. We confirmed normal Oct3/4 expres-
sion at protein levels by Western blot (Figure 6B). The
overall gene expression profiles were similar between con-
trol ES cells and ESG1-/- ES cells. Several genes exhibited a
greater than two-fold reduction in ESG1-/- cells, including
Krt1-8, Pem, Ctgf, Ptgs2, Igf2 and Inhba. These genes might
be regulated directly or indirectly by ESG1. Since ESG1
contains a KH-type RNA-binding domain, it may stabilize
mRNA of these genes. Further studied are required to clar-
ify this possibility.
To generate ESG1-knockout mice, we injected β-geo-
ESG1+/- ES cell clones into the blastocysts of C57BL6 mice.
We obtained germline transmission from three clones. We
obtained ESG1-/- mice at the Mendelian ratios (36 wild-
type, 69 ESG1+/-, and 45 ESG1-/-) from intercrosses of
ESG1+/- mice. These animals exhibited normal develop-
ment, gross appearance, and fertility (not shown). Histo-
logical examination of testis and ovary could not identify
any abnormalities (not shown). These data demonstrated
that ESG1 is dispensable for both mouse development
and germ cell formation.
We also generated ES cells from blastocysts obtained by
intercrosses of ESG1+/- males and ESG1-/- females. Of the
eight ES cell lines established, two clones were ESG1-/-.
These ESG1-null ES cells demonstrated normal morphol-
ogy, proliferation, and differentiation (not shown), con-
firming that ESG1 is dispensable in ES cells.
Conclusion
To analyze the physiological roles of ESG1, we identified
the mouse gene on chromosome 9 and deleted it by
homologous recombination in ES cells. Despite specific
expression in early embryos, germ cells, and pluripotent
BAC clones containing the ESG1 gene and a duplication pseudogene (PS) Figure 2
BAC clones containing the ESG1 gene and a duplication pseudogene (PS). A) Localization of the gene and PS on 
chromosome 9. B) Sequence comparison of the gene and PS revealed that these are homologous from eight base pairs 
upstream of the first exon to 675 bp downstream of the third exon. Substitution mutations are indicated by black lines. The 
insertion is indicated by an open triangle.
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cells, our data demonstrated that ESG1 is dispensable for
mouse development, germ cell formation, and ES cell self-
renewal.
Methods
Identification and analyses of BAC clones containing the 
mouse ESG1 gene
To identify bacterial artificial chromosome (BAC) clones
containing mouse ESG1 gene, we performed PCR-based
screening of mouse BAC library DNA pools (Research
Genetics) using the pH34-u38 (5'-GAAGTCTGGTTCCTT-
GGCAGG-3') and pH34-L394 (5'-ACTCGATACACT-
GGCCTAGC-3') primers. Following restriction enzyme
digestion, we performed Southern blot analyses of BAC
clones as described [20] using the pH34-U258 (5'-CTC-
GAGTGTACAGTCAAGTGGTTGCTGGGA-3'), pH34-U65
(5'-GTGACCCTCGTGACCCGTAA-3'), pH34-intron1L
(5'-CTGCGTGAGAGAAACACCAAACAGGC-3'), pH34-
L545 (5'-TGTGAATGGGAAGGTTACCACTCT-3') and
pH34-SCL1 (5'-GCCCTCTTCTGGTTTGTCTCGAAAT-3')
probes. Hybridization with these probes revealed bands
containing either the ESG1 gene or pseudogenes.
To sequence the region containing the mouse ESG1 gene
and the 3' flanking region, we subcloned a ~15 kbp XhoI-
SalI fragment into the pZERO-2 vector (Invitrogen). Hin-
dIII- or EcoRI-digested fragments of this vector were then
cloned into pBluescript KS(-) for sequencing. To sequence
the ESG1 pseudogene and the 3' flanking region, an 8 kbp
NotI/XhoI fragment was cloned into pBluescript KS(-).
BamHI- or PstI- fragments of this vector were also cloned
into pBluescript KS(-). To identify the sequence contain-
ing the 5' flanking regions of the ESG1  gene and the
related pseudogenes, we used a TOPO walker kit (Invitro-
gen) with the pH34-T2L (5'-ACTAGTCGCAGCAG-
GGATCCAGGAATATCT-3') and pH34-L394 primers. The
resulting sequence was cloned into pCR2.1 (Invitrogen).
We obtained a ~6 kbp band from the NsiI-digensted
library; XbaI-, SpeI-, EcoRI-, and PstI-digested fragments of
this band were cloned into pBluescript KS(-) for sequenc-
ing. This fragment contained the 5' flanking region of the
ESG1 gene. A ~3 kbp fragment, obtained from the SacI-
digested library, was cloned into pCR2.1 for sequencing.
This fragment was contained the 5' region flanking the
pseudogene.
Construction of ESG1 targeting vectors
We replaced all of the ESG1 exons with two targeting vec-
tors containing either an IRES-β-geo cassette [21] or an
IRES-HygR cassette by promoter trap selection. We ampli-
fied the 5' arm (1.8 kbp) using KOD plus (TOYOBO) with
the pH34-targetpair5-U (5'-CCGCGGAAAGTCAAGA-
GATTGGGTGG-3') and pH34-targetpair5-L (5'-GCG-
GCCGCCTTTACGGGTCACGAGGGTCAC-3') primers.
Promoter/enhancer activity of the ESG1 gene and pseudogene Figure 3
Promoter/enhancer activity of the ESG1 gene and pseudogene. DNA fragments of ~6 kbp isolated from the 5' flanking 
regions of the gene and PS were transferred into luciferase reporter plasmids. We introduced the reporter genes into undiffer-
entiated ES cells (open columns), retinoic acid-treated ES cells (grey columns), and NIH3T3 cells (closed columns). Data repre-
sent the averages and standard deviations of three independent experiments.
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The 3' arm (5.8 kbp) was amplified using the pH34-
targetpair3-U (5'-TGTGGCCAGTGTTTGGTTCT-
GGCGGG-3') and pH34-targetpair3-L (5'-CTCGAG-
GACTCGCCATTCTAGCCAAG-3') primers. The IRES β-
geo or IRES HygR cassettes were ligated in between the
two PCR fragments. The diphtheria toxin A cassette was
placed downstream of the 3' arm. After linearization with
SacII, these targeting vectors were electroporated into 2.0
× 107 RF8 ES cells [22] using a Gene pulser (BIORAD).
Transfected cells were selected with 250 µg/mL G418 or
100  µg/mL hygromycin B, respectively. Genomic DNA
from G418- or hygromycin B-resistant colonies was
screened for homologous recombination by Southern
blotting.
Southern blot screening for homologous recombination
ES cells genomic DNA was extracted with PUREGENE™
Cell Lysis Solution (Gentra systems). For 5' Southern blot
analysis, genomic DNA was first digested with PstI, then
separated on an 0.8% agarose gel and transferred to a
nylon membrane as described [20]. A 560 bp 5' probe was
amplified using the ESG1S5 (5'- GATGGTGGTGGTGACT-
CAGAG -3') and ESG1AS5 as (5'- CCTCCATTGCCTC-
TATATCAG -3') primers. The probe specifically labeled an
18 kbp band from the wild-type locus, a 15 kbp band
from the β-geo locus, and a 12 kbp band from the HygR
locus. Genomic DNA was also digested with SpeI for 3'
Southern blot analysis. A 1,010 bp 3' probe was amplified
with the pH34U-8000 (5'- CCAACCAGCCAGAGTT-
Targeted disruption of the mouse ESG1 gene Figure 4
Targeted disruption of the mouse ESG1 gene. A) Targeting strategy. Homologous regions are indicated by thick lines. 
Recognition sites of PstI (P) and SpeI (S), which were used for Southern blot analyses, are shown. The gene encoding diphtheria 
toxin A (DTA) was inserted at the 3' end of the targeting vectors to facilitate negative selection. B) Southern blot analyses con-
firming homologous recombination. WT, wild-type ES cells; β, β-geo +/- ES cells; H, HygR +/- ES cells; -/-, ESG1-null ES cells. 
Numbers indicate clone numbers. C) Northern blot (upper) and western blot (lower) analyses of wild-type ES cells (WT), 
ESG1-null ES cells (-/-, three clones) and heterozygous ES cells (+/-). Northern blot was performed as previously described 
[20]. To confirm the loading of equal amounts of RNA, ethidium bromide staining of ribosomal RNA is also shown (middle).
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TCAGTTAT -3') and pH34L-9000 (5'-GATAAGCTGCT-
GCCAAAAGACAAG -3') primers. The probe hybridized to
an 11.5 kbp band from the wild-type locus, a 12.5 kbp
band from the β-geo locus, and a 9.5 kbp band from the
HygR locus.
Generation of anti-ESG1 polyclonal antibodies
The coding sequence of Esg1 was amplified by PCR with
the pH34-gw-s (5'- AAAAAGCAGGCTGGATGATGGT-
GACCCTCGTGA-3') and pH34-gw-as (5'- AGAAAGCT-
GGGTCTGCATCCAGGTCGGAGACA-3') primers. To
Analyses of ESG1-null ES cells Figure 5
Analyses of ESG1-null ES cells. A) The morphology of ESG1-null ES cell colonies grown on STO feeder cells. B) Growth 
curve of wild-type (WT), ESG1-null (-/-) and heterozygous (+/-) ES cells. Each clone (1 × 104 cells/well) was plated in 24-well 
plates. Cell numbers were determined with a Coulter counter at 2, 4, and 6 days. Data of +/- and -/- cells are shown as aver-
ages and standard deviations of three independent clones. C) A section of teratoma derived from ESG1-null ES cells (hematox-
ylin & eosin staining).
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construct pDONR-pH34, the resulting PCR product was
subcloned into pDONR201 (Invitrogen). pDONR-pH34
was interacted with pDEST17 (Invitrogen) by LR recombi-
nation. After introduction of the resulting expression vec-
tor pDEST17-pH34 into BL21-AI E. coli (Invitrogen),
recombinant protein production was induced according
to the manufacture's protocol. Histidine-tagged ESG1 was
purified using Ni-nitrilotriacetic acid agarose (Qiagen)
under denaturing conditions in the presence of 8 M urea.
After dialysis against 6 M urea, the recombinant proteins
were injected into New Zealand White rabbits to generate
anti-ESG1 polyclonal antibodies.
Western blot
After preparation of ES cell extracts with M-Per (Pierce),
cellular proteins were separated on sodium dodecyl sul-
fate (SDS)-14% polyacrylamide gels and transferred to
nitrocellulose membranes (Millipore). Membranes were
incubated with anti-ESG1 (1/500 dilution), anti-Oct3/4
(1/500; Santa Cruz Biotechnology), anti-CDK4 (1/200;
Santa Cruz Biotechnology), and anti-GFP (1/1000; MBL)
primary antibodies. Horseradish peroxidase-conjugated
anti-rabbit and anti-mouse immunoglobulins (1/5000;
Cell Signaling) were used to detect antibody binding. We
visualized bound antibody with an ECL Western Blotting
Detection System (Amersham).
Derivation of ESG1-deficient ES cells from blastocysts
Esg1+/-or ESG1-/- mutant female mice were injected with
Tamoxifen (10 µg) and Depo-provera (1 mg) subcutane-
ously on the third day of pregnancy. Four days later,
embryos in diapause were flushed out of the uterus and
cultured on STO feeder cells in four-well plates in Dul-
becco's Modified Eagle Medium (DMEM) supplemented
with 20% Fetal Bovine Serum (Hyclone), 0.1 mM Non-
Essential Amino Acids (Invitrogen), 2 mM L-glutamine
(Invitrogen), 50 U/ml Penicillin-Streptomysin (Invitro-
gen), and 0.11 mM 2-mercaptoethanol (Invitrogen). After
six days, the central mass of each explant was harvested,
rinsed in PBS, and placed in a drop of trypsin for a few
minutes. The cell mass was collected with a finely drawn-
out Pasteur pipette preloaded with medium, ensuring
minimal carryover of the trypsin. The cells were gently
transfered into a fresh well with 20% FBS-containing
medium. The resulting primary ES cell colonies were indi-
vidually passaged into wells of four-well plates containing
Gene expression analyses of ESG1-null ES cells Figure 6
Gene expression analyses of ESG1-null ES cells. A) DNA microarray analyses. Total RNA from wild-type ES cells and 
ESG1-null ES cells were labeled with Cy3 and Cy5, respectively. Samples were hybridized to Agilent Mouse Developmental 
Microarrays. The averages of two independent clones are shown. B) Western blot analyses. Cell lysates from ESG1+/- and 
ESG1-/- cells were examined for expression of ESG1, Oct3/4 and CDK4 with immunoblotting.
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STO feeder cell layers. Thereafter, cells were expanded by
trypsinization of the entire culture.
Microarrays
Total RNA from wild-type ES cells and ESG1-/- ES cells was
labeled with Cy3 and Cy5, respectively. The samples were
hybridized to a Mouse Development Microarray (Algi-
lent) according to the manufacturer's protocol. Arrays
were scanned with a G2565BA Microarray Scanner System
(Agilent). Hybridization was repeated with two independ-
ent clones. Data were analyzed with GeneSprings software
(Silico Genetics).
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